Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Adrenergic, alpha-2 | 6 | 2016 | 39 | 2.030 |
Why?
|
| Pain | 9 | 2016 | 251 | 1.550 |
Why?
|
| Estradiol | 6 | 2016 | 262 | 1.150 |
Why?
|
| Clonidine | 5 | 2016 | 52 | 1.100 |
Why?
|
| Pain Measurement | 11 | 2024 | 171 | 1.020 |
Why?
|
| Sex Characteristics | 6 | 2016 | 230 | 0.960 |
Why?
|
| Estrogens | 6 | 2016 | 202 | 0.850 |
Why?
|
| Analgesics | 3 | 2016 | 54 | 0.750 |
Why?
|
| Hyperalgesia | 2 | 2016 | 18 | 0.640 |
Why?
|
| Rats, Sprague-Dawley | 18 | 2018 | 1618 | 0.640 |
Why?
|
| Testosterone | 5 | 2016 | 193 | 0.610 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2014 | 93 | 0.570 |
Why?
|
| Nociceptors | 2 | 2006 | 32 | 0.530 |
Why?
|
| Ovariectomy | 9 | 2016 | 105 | 0.510 |
Why?
|
| Peptide Fragments | 5 | 2003 | 308 | 0.510 |
Why?
|
| Choline O-Acetyltransferase | 6 | 2003 | 34 | 0.500 |
Why?
|
| Serum Albumin, Bovine | 1 | 2014 | 51 | 0.460 |
Why?
|
| Cerebral Cortex | 4 | 2002 | 290 | 0.450 |
Why?
|
| Hippocampus | 5 | 2002 | 561 | 0.440 |
Why?
|
| Rats | 16 | 2016 | 3483 | 0.420 |
Why?
|
| Trigeminal Nuclei | 2 | 2009 | 11 | 0.420 |
Why?
|
| Aftercare | 2 | 2022 | 19 | 0.410 |
Why?
|
| Substance P | 3 | 2004 | 26 | 0.400 |
Why?
|
| Receptors, Opioid, kappa | 3 | 2018 | 22 | 0.400 |
Why?
|
| Spinal Cord | 5 | 2018 | 94 | 0.390 |
Why?
|
| Somatostatin | 4 | 2003 | 22 | 0.370 |
Why?
|
| Analgesics, Opioid | 3 | 2022 | 197 | 0.360 |
Why?
|
| Adrenergic alpha-Antagonists | 5 | 2009 | 31 | 0.320 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 69 | 0.320 |
Why?
|
| Maze Learning | 6 | 2003 | 105 | 0.320 |
Why?
|
| Animals | 21 | 2018 | 15081 | 0.310 |
Why?
|
| Pentazocine | 2 | 2018 | 3 | 0.300 |
Why?
|
| Trigeminal Caudal Nucleus | 1 | 2006 | 6 | 0.290 |
Why?
|
| Hot Temperature | 5 | 2016 | 128 | 0.280 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 360 | 0.270 |
Why?
|
| Male | 20 | 2024 | 20025 | 0.260 |
Why?
|
| Cerebral Ventricles | 3 | 2001 | 23 | 0.260 |
Why?
|
| Pons | 1 | 2004 | 9 | 0.250 |
Why?
|
| Signal Transduction | 1 | 2014 | 1908 | 0.250 |
Why?
|
| N-Methylaspartate | 4 | 2009 | 57 | 0.240 |
Why?
|
| Female | 15 | 2024 | 20969 | 0.210 |
Why?
|
| Receptors, Opioid | 3 | 2013 | 51 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 1039 | 0.200 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 58 | 0.200 |
Why?
|
| Drug Interactions | 3 | 2014 | 141 | 0.190 |
Why?
|
| Parathion | 1 | 2001 | 3 | 0.190 |
Why?
|
| Reaction Time | 2 | 2014 | 143 | 0.190 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2001 | 43 | 0.190 |
Why?
|
| Neurotoxins | 1 | 2001 | 57 | 0.190 |
Why?
|
| Survivors | 1 | 2021 | 136 | 0.180 |
Why?
|
| Adrenergic alpha-Agonists | 3 | 2008 | 34 | 0.170 |
Why?
|
| Yohimbine | 3 | 2009 | 26 | 0.170 |
Why?
|
| Neuropeptide Y | 1 | 1998 | 24 | 0.160 |
Why?
|
| Pain Threshold | 4 | 2016 | 28 | 0.160 |
Why?
|
| Neuropeptides | 1 | 1999 | 59 | 0.160 |
Why?
|
| Time Factors | 3 | 2014 | 1742 | 0.160 |
Why?
|
| Opioid Peptides | 2 | 2009 | 28 | 0.150 |
Why?
|
| Motor Activity | 1 | 2001 | 418 | 0.150 |
Why?
|
| Behavior, Animal | 4 | 2008 | 314 | 0.150 |
Why?
|
| Brain | 3 | 2003 | 1346 | 0.150 |
Why?
|
| Estrogen Antagonists | 1 | 2016 | 28 | 0.140 |
Why?
|
| Receptors, Opioid, mu | 1 | 2016 | 55 | 0.140 |
Why?
|
| Aging | 1 | 2001 | 664 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2021 | 389 | 0.130 |
Why?
|
| Orchiectomy | 3 | 2010 | 35 | 0.130 |
Why?
|
| Sex Factors | 2 | 2008 | 898 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 156 | 0.110 |
Why?
|
| Cattle | 1 | 2014 | 477 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 433 | 0.100 |
Why?
|
| Patient Discharge | 2 | 2022 | 93 | 0.100 |
Why?
|
| Analgesia | 1 | 2010 | 20 | 0.100 |
Why?
|
| Testosterone Propionate | 1 | 2009 | 3 | 0.090 |
Why?
|
| Catheterization | 1 | 2009 | 24 | 0.090 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 41 | 0.090 |
Why?
|
| Infusions, Parenteral | 2 | 1999 | 12 | 0.090 |
Why?
|
| Brain Chemistry | 2 | 2001 | 140 | 0.090 |
Why?
|
| Arrestin | 1 | 2008 | 7 | 0.080 |
Why?
|
| Alzheimer Disease | 3 | 2003 | 905 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2010 | 550 | 0.080 |
Why?
|
| Adolescent | 3 | 2024 | 5363 | 0.070 |
Why?
|
| Adult | 4 | 2024 | 11712 | 0.070 |
Why?
|
| Catecholamines | 1 | 2006 | 44 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2022 | 2026 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 146 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2008 | 933 | 0.070 |
Why?
|
| Dioxanes | 1 | 2004 | 11 | 0.060 |
Why?
|
| Injections, Intraventricular | 2 | 2002 | 64 | 0.060 |
Why?
|
| Injections, Spinal | 2 | 2016 | 13 | 0.060 |
Why?
|
| Estrous Cycle | 2 | 2016 | 35 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 132 | 0.060 |
Why?
|
| Ginkgo biloba | 1 | 2002 | 3 | 0.050 |
Why?
|
| Young Adult | 2 | 2024 | 4268 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2002 | 73 | 0.050 |
Why?
|
| Prescriptions | 1 | 2021 | 18 | 0.050 |
Why?
|
| Melatonin | 1 | 2002 | 82 | 0.050 |
Why?
|
| Trauma Centers | 1 | 2021 | 79 | 0.050 |
Why?
|
| Mice | 3 | 2008 | 5913 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2021 | 100 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 974 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2021 | 117 | 0.050 |
Why?
|
| Entorhinal Cortex | 1 | 2001 | 13 | 0.050 |
Why?
|
| Acoustic Stimulation | 1 | 2001 | 66 | 0.050 |
Why?
|
| Violence | 1 | 2021 | 134 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1999 | 4 | 0.040 |
Why?
|
| Osmotic Pressure | 1 | 1999 | 21 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2003 | 517 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2024 | 1492 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2024 | 1378 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2010 | 88 | 0.040 |
Why?
|
| Humans | 5 | 2024 | 37093 | 0.040 |
Why?
|
| Antioxidants | 1 | 2002 | 416 | 0.040 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 1998 | 7 | 0.040 |
Why?
|
| Ibotenic Acid | 1 | 1998 | 5 | 0.040 |
Why?
|
| Cholinergic Agents | 1 | 1998 | 8 | 0.040 |
Why?
|
| Cholinergic Fibers | 1 | 1998 | 10 | 0.040 |
Why?
|
| Ribosome Inactivating Proteins, Type 1 | 1 | 1998 | 7 | 0.040 |
Why?
|
| Mutation | 1 | 2003 | 1095 | 0.040 |
Why?
|
| Immunotoxins | 1 | 1998 | 12 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 1998 | 48 | 0.040 |
Why?
|
| Morphine | 1 | 2018 | 85 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 494 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 1998 | 290 | 0.040 |
Why?
|
| Child | 1 | 2022 | 3131 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 1997 | 1371 | 0.030 |
Why?
|
| United States | 1 | 2022 | 4223 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2013 | 381 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 859 | 0.020 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 2010 | 7 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2010 | 14 | 0.020 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2010 | 15 | 0.020 |
Why?
|
| Naltrexone | 1 | 2010 | 38 | 0.020 |
Why?
|
| Mustard Plant | 1 | 2009 | 7 | 0.020 |
Why?
|
| Irritants | 1 | 2009 | 8 | 0.020 |
Why?
|
| Plant Oils | 1 | 2009 | 18 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 623 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2003 | 617 | 0.020 |
Why?
|
| Castration | 1 | 2008 | 34 | 0.020 |
Why?
|
| Middle Aged | 1 | 2021 | 10129 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2006 | 57 | 0.020 |
Why?
|
| Inflammation | 1 | 2010 | 618 | 0.020 |
Why?
|
| Presenilin-1 | 1 | 2003 | 27 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 60 | 0.010 |
Why?
|
| Memory | 1 | 2003 | 170 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2002 | 224 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 674 | 0.010 |
Why?
|
| Plant Extracts | 1 | 2002 | 286 | 0.010 |
Why?
|